Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Emergency and Critical Care

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Adverse events

Canakinumab showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 1.02 [0.86, 1.21]
1 study · 454 participants
Moderate

Serious adverse eventsÂ

Canakinumab showed no clear difference in serious adverse eventsÂ compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐1 blocking agents for treating COVID‐19 2022 · Cochrane Headline outcomes only
RR 0.8 [0.57, 1.13]
2 studies · 499 participants
Low